» Articles » PMID: 28396605

Bypassing Adverse Injection Reactions to Nanoparticles Through Shape Modification and Attachment to Erythrocytes

Overview
Journal Nat Nanotechnol
Specialty Biotechnology
Date 2017 Apr 12
PMID 28396605
Citations 65
Authors
Affiliations
Soon will be listed here.
Abstract

Intravenously injected nanopharmaceuticals, including PEGylated nanoparticles, induce adverse cardiopulmonary reactions in sensitive human subjects, and these reactions are highly reproducible in pigs. Although the underlying mechanisms are poorly understood, roles for both the complement system and reactive macrophages have been implicated. Here, we show the dominance and importance of robust pulmonary intravascular macrophage clearance of nanoparticles in mediating adverse cardiopulmonary distress in pigs irrespective of complement activation. Specifically, we show that delaying particle recognition by macrophages within the first few minutes of injection overcomes adverse reactions in pigs using two independent approaches. First, we changed the particle geometry from a spherical shape (which triggers cardiopulmonary distress) to either rod- or disk-shape morphology. Second, we physically adhered spheres to the surface of erythrocytes. These strategies, which are distinct from commonly leveraged stealth engineering approaches such as nanoparticle surface functionalization with poly(ethylene glycol) and/or immunological modulators, prevent robust macrophage recognition, resulting in the reduction or mitigation of adverse cardiopulmonary distress associated with nanopharmaceutical administration.

Citing Articles

Advances in targeted therapy for tumor with nanocarriers: A review.

Cheng H, Liao J, Ma Y, Sarwar M, Yang H Mater Today Bio. 2025; 31:101583.

PMID: 40061211 PMC: 11889621. DOI: 10.1016/j.mtbio.2025.101583.


Effect of Lipid Nanoparticle Physico-Chemical Properties and Composition on Their Interaction with the Immune System.

Catenacci L, Rossi R, Sechi F, Buonocore D, Sorrenti M, Perteghella S Pharmaceutics. 2025; 16(12.

PMID: 39771501 PMC: 11728546. DOI: 10.3390/pharmaceutics16121521.


Advances in drug delivery systems utilizing blood cells and their membrane-derived microvesicles.

He A, Huang Y, Cao C, Li X Drug Deliv. 2024; 31(1):2425156.

PMID: 39520082 PMC: 11552282. DOI: 10.1080/10717544.2024.2425156.


Tailoring biomaterials for vaccine delivery.

Zhuo Y, Zeng H, Su C, Lv Q, Cheng T, Lei L J Nanobiotechnology. 2024; 22(1):480.

PMID: 39135073 PMC: 11321069. DOI: 10.1186/s12951-024-02758-0.


Polymersomes with splenic avidity target red pulp myeloid cells for cancer immunotherapy.

Wauters A, Scheerstra J, van Leent M, Teunissen A, Priem B, Beldman T Nat Nanotechnol. 2024; 19(11):1735-1744.

PMID: 39085390 PMC: 11567884. DOI: 10.1038/s41565-024-01727-w.


References
1.
Geng Y, Dalhaimer P, Cai S, Tsai R, Tewari M, Minko T . Shape effects of filaments versus spherical particles in flow and drug delivery. Nat Nanotechnol. 2008; 2(4):249-55. PMC: 2740330. DOI: 10.1038/nnano.2007.70. View

2.
Moghimi S . Recent developments in polymeric nanoparticle engineering and their applications in experimental and clinical oncology. Anticancer Agents Med Chem. 2006; 6(6):553-561. DOI: 10.2174/187152006778699130. View

3.
Laing R, Milne L, Leen C, Malcolm G, Steers A . Anaphylactic reactions to liposomal amphotericin. Lancet. 1994; 344(8923):682. DOI: 10.1016/s0140-6736(94)92116-4. View

4.
Keyes Jr J, Wilson G, Quinonest J . An evaluation of lung uptake of colloid during liver imaging. J Nucl Med. 1973; 14(9):687-91. View

5.
Wibroe P, Ahmadvand D, Oghabian M, Yaghmur A, Moghimi S . An integrated assessment of morphology, size, and complement activation of the PEGylated liposomal doxorubicin products Doxil®, Caelyx®, DOXOrubicin, and SinaDoxosome. J Control Release. 2015; 221:1-8. DOI: 10.1016/j.jconrel.2015.11.021. View